UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRINCETON, N.J., Dec. 05, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) to 14 new employees in connection with their employment with UroGen. These new team members will support the ongoing commercialization of Jelmyto ® (mitomycin) for pyelocalyceal solution and ZUSDURI™ (mitomycin) for intravesical solution, UroGen's only approved products, and the continued development of UroGen's pipeline.

GlobeNewsWire • Dec 5, 2025

UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference

PRINCETON, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will present at the Piper Sandler 37th Annual Healthcare Conference to take place on December 2-4, 2025.

GlobeNewsWire • Nov 25, 2025

UroGen Pharma: Strong Potential As Zusduri Commercialization Accelerates

UroGen Pharma (URGN) is rated a Strong Buy, with a $33/share price target by end of 2026, driven by its proprietary RTGel technology. URGN's newly approved Zusduri targets a large bladder cancer market, offering a non-surgical alternative, with strong clinical results and significant revenue potential. Jelmyto's commercial success in a smaller market supports confidence in Zusduri's launch, with analysts projecting URGN to reach profitability by 2027.

Seeking Alpha • Nov 25, 2025

UroGen Pharma Ltd. (URGN) Q3 2025 Earnings Call Transcript

UroGen Pharma Ltd. ( URGN ) Q3 2025 Earnings Call November 6, 2025 10:00 AM EST Company Participants Vincent Perrone - Senior Director of Investor Relations Elizabeth Barrett - President, CEO & Director Mark Schoenberg - Chief Medical Officer David Lin - Chief Commercial Officer Christopher Degnan - Chief Financial Officer Conference Call Participants Tara Bancroft - TD Cowen, Research Division Paul Jeng - Guggenheim Securities, LLC, Research Division Kelsey Goodwin - Piper Sandler & Co., Research Division Raghuram Selvaraju - H.C.

Seeking Alpha • Nov 7, 2025

UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum

Reported three-month complete response rate of 77.8% from the Phase 3 UTOPIA trial of UGN-103, consistent with ENVISION results; FDA agreed to regulatory plan to submit an NDA based on data from the UTOPIA trial ZUSDURI received unique J-Code (J9282) in October 2025, effective January 1, 2026 ZUSDURI achieved net product revenue of $1.8 million in Q3 2025; October 2025 preliminary demand revenue estimate of $4.5 million reflecting accelerating growth entering Q4 2025 JELMYTO® achieved net product revenue of $25.7 million in Q3 2025, representing YoY underlying demand revenue growth of 13% $127.4 million in cash, cash equivalents and marketable securities as of September 30, 2025 Conference call and webcast to be held today at 10:00 AM ET PRINCETON, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.

GlobeNewsWire • Nov 6, 2025

Urogen Pharma (URGN) Reports Q3 Loss, Misses Revenue Estimates

Urogen Pharma (URGN) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to a loss of $0.55 per share a year ago.

Zacks Investment Research • Nov 6, 2025

UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial

PRINCETON, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced robust preliminary results from its ongoing Phase 3 UTOPIA trial, demonstrating a 77.8% three-month complete response (CR) rate (95% CI, 68.3%, 85.5%) with UGN-103 (mitomycin) for intravesical solution in patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). This result is consistent with the 79.6% three-month CR rate (95% CI, 73.9%, 84.5%) observed following treatment with ZUSDURI in the pivotal ENVISION trial. In addition, the U.S. Food and Drug Administration (FDA) agreed that CR and durability results from the UTOPIA trial can support the submission of a New Drug Application (NDA) for UGN-103 for recurrent LG-IR-NMIBC.

GlobeNewsWire • Nov 6, 2025

UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference

PRINCETON, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.

GlobeNewsWire • Nov 4, 2025

UroGen: Expect Rough Patch Before Strong Recovery In 2026

UroGen Pharma is revisited after a previous Strong Buy rating, with UroGen having increased ~95% since then. The article reflects on UroGen's RTGel technology, which supports JELMYTO and ZUSDURI, its two FDA-approved products. JELMYTO has grown its revenues, but they are starting to taper off.

Seeking Alpha • Nov 2, 2025

UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025

Conference Call and Webcast Scheduled for Thursday, November 6th, 2025, at 10:00 AM ET Conference Call and Webcast Scheduled for Thursday, November 6th, 2025, at 10:00 AM ET

GlobeNewsWire • Oct 30, 2025